Innate Pharma S.A.
IPHYFOTCHealthcare● Active
$2.25
+$0.60(+36.36%)
Market Cap$211282398
P/E Ratio—
52W High$2.25
52W Low$1.31
Innate Pharma S.A. (IPHYF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IPHYF · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 26, 2026EPS Actual
-$0.35
Est. -$0.35 · +0.0%
Revenue
$0.00B
Est. $0.01B · -15.4%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 26, 2026
After Market Close
▼ Miss Revenue✓ 2-Quarter EPS Beat Streak
IPHYF reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Sep 17, 2026 | -$0.33 | — | — | — | $0.01B | — |
| — Q1 FY2026 | Mar 26, 2026 | -$0.35 | -$0.35 | +0.0% | $0.00B | $0.01B | -15.4% |
| ▲ Q3 FY2025 | Sep 17, 2025 | -$0.33 | -$0.29 | +12.4% | $0.01B | $0.00B | +192.0% |
| ▼ Q2 FY2025 | May 12, 2025 | -$0.26 | -$0.32 | -19.6% | $0.00B | $0.02B | -98.4% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -$0.30 | -$0.33 | -9.8% | $0.01B | $0.01B | -0.1% |
| ▲ Q2 FY2024 | May 14, 2024 | -$0.45 | -$0.13 | +71.5% | $0.02B | $0.02B | +27.0% |
| ▼ Q3 FY2023 | Sep 14, 2023 | $0.09 | $0.02 | -74.4% | $0.04B | $0.07B | -37.1% |
| ▼ Q1 FY2023 | Mar 23, 2023 | -$0.42 | -$0.87 | -107.3% | $0.01B | $0.02B | -51.4% |
Q3 FY2026
Sep 17, 2026
EPS Actual
—
EPS Est.
-$0.33
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 26, 2026
EPS Actual
-$0.35
EPS Est.
-$0.35
EPS Surpr.
+0.0%
Revenue
$0.00B
Q3 FY2025
Sep 17, 2025Beat
EPS Actual
-$0.29
EPS Est.
-$0.33
EPS Surpr.
+12.4%
Revenue
$0.01B
Q2 FY2025
May 12, 2025Miss
EPS Actual
-$0.32
EPS Est.
-$0.26
EPS Surpr.
-19.6%
Revenue
$0.00B
Q4 FY2024
Nov 13, 2024Miss
EPS Actual
-$0.33
EPS Est.
-$0.30
EPS Surpr.
-9.8%
Revenue
$0.01B
Q2 FY2024
May 14, 2024Beat
EPS Actual
-$0.13
EPS Est.
-$0.45
EPS Surpr.
+71.5%
Revenue
$0.02B
Q3 FY2023
Sep 14, 2023Miss
EPS Actual
$0.02
EPS Est.
$0.09
EPS Surpr.
-74.4%
Revenue
$0.04B
Q1 FY2023
Mar 23, 2023Miss
EPS Actual
-$0.87
EPS Est.
-$0.42
EPS Surpr.
-107.3%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2025 | $-0.12 | $-0.12 | $-0.12 | 1 |
| Q3 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2025 | $-0.28 | $-0.28 | $-0.28 | 1 |
| Q2 FY2024 | $-0.34 | $-0.34 | $-0.34 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2026 | Mar 26, 2026 | +0.0% | $1.37 | $1.37 | +0.00% |
| ▲ Q3 FY2025 | Sep 17, 2025 | +12.4% | $2.00 | $2.00 | +0.00% |
| ▼ Q2 FY2025 | May 12, 2025 | -19.6% | $1.45 | $1.45 | +0.00% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -9.8% | $1.28 | $1.28 | +0.00% |
| ▲ Q2 FY2024 | May 14, 2024 | +71.5% | $2.20 | $2.77 | +25.91% |
| ▼ Q3 FY2023 | Sep 14, 2023 | -74.4% | $3.00 | $3.00 | +0.00% |
| ▼ Q1 FY2023 | Mar 23, 2023 | -107.3% | $3.08 | $3.08 | +0.00% |
| ▼ Q4 FY2022 | Nov 14, 2022 | -79.2% | $2.08 | $2.08 | +0.00% |
Q1 FY2026+0.00%
Report Date
Mar 26, 2026
EPS Beat/Miss
+0.0%
Price Before
$1.37
Price After
$1.37
Q3 FY2025+0.00%
Report Date
Sep 17, 2025
EPS Beat/Miss
+12.4%
Price Before
$2.00
Price After
$2.00
Q2 FY2025+0.00%
Report Date
May 12, 2025
EPS Beat/Miss
-19.6%
Price Before
$1.45
Price After
$1.45
Q4 FY2024+0.00%
Report Date
Nov 13, 2024
EPS Beat/Miss
-9.8%
Price Before
$1.28
Price After
$1.28
Q2 FY2024+25.91%
Report Date
May 14, 2024
EPS Beat/Miss
+71.5%
Price Before
$2.20
Price After
$2.77
Q3 FY2023+0.00%
Report Date
Sep 14, 2023
EPS Beat/Miss
-74.4%
Price Before
$3.00
Price After
$3.00
Q1 FY2023+0.00%
Report Date
Mar 23, 2023
EPS Beat/Miss
-107.3%
Price Before
$3.08
Price After
$3.08
Q4 FY2022+0.00%
Report Date
Nov 14, 2022
EPS Beat/Miss
-79.2%
Price Before
$2.08
Price After
$2.08
Avg Beat Reaction+8.64%
Avg Miss Reaction+0.00%
Beat Rate3 / 8 quarters
Largest Move+25.91% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IPHYF ends December
Innate Pharma S.A. (IPHYF) most recently reported earnings on March 26, 2026 for Q1 FY2026, posting EPS of $-0.35 (in line with the analyst consensus of $-0.35). IPHYF has beaten EPS estimates for 2 consecutive quarters. The next IPHYF earnings date is expected around September 1, 2026.
Each quarter, investors track IPHYF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IPHYF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IPHYF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IPHYF earnings · 4 questionsInnate Pharma S.A.'s next earnings report is expected around September 1, 2026. IPHYF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IPHYF historically reports after market close (AMC).
IPHYF earnings datewhen is IPHYF earningsIPHYF next earnings datewhen does IPHYF report earningsIPHYF earnings calendar
▸ Source: FMP · Innate Pharma S.A. SEC filings · US GAAP · Innate Pharma S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026